NCT00182390

Brief Summary

Hypothesis: That a high hemoglobin threshold for transfusion in extremely low birth weight (ELBW) infants is associated with a lower rate of survival without severe morbidity (defined as one or more of retinopathy of prematurity, bronchopulmonary dysplasia, or periventricular leukomalacia/ventriculomegaly). Primary Objective: To determine whether either a liberal or more restrictive threshold of hemoglobin level for red cell transfusion in ELBW infants is safer, by randomizing to either a high transfusion hemoglobin threshold or a low transfusion hemoglobin threshold. Follow-up at a corrected age of 18 months represents a conventional age at which to first assess neurodevelopmental outcomes, and to predict long-term outcomes.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
424

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Feb 2001

Longer than P75 for phase_3

Geographic Reach
3 countries

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2001

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2003

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2005

Completed
Last Updated

September 24, 2015

Status Verified

September 1, 2015

Enrollment Period

2 years

First QC Date

September 13, 2005

Last Update Submit

September 22, 2015

Conditions

Keywords

ELBW premature infantsneonatal transfusionbronchopulmonary dysplasiaperiventricular leukomalaciaventriculomegalyretinopathy of prematurity

Outcome Measures

Primary Outcomes (2)

  • Combined mortality or survival to tertiary hospital discharge without severe morbidity (BPD, severe ROP or brain injury)

    neonatal phase

  • Combined mortality or survival with neurodevelopmental disability (non-ambulatory cerebral palsy, blindness, deafness, cognitive delay)

    follow-up phase 18 months corrected age

Secondary Outcomes (20)

  • growth in weight and head circumference

    neonatal phase

  • time to extubation

    neonatal phase

  • time on oxygen

    neonatal phase

  • length of hospital stay until discharge home

    neonatal phase

  • confirmed necrotizing enterocolitis

    neonatal phase

  • +15 more secondary outcomes

Interventions

Eligibility Criteria

AgeUp to 48 Hours
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • birth weight \<1000g
  • postnatal age \<48 hours
  • no transfusion beyond first 6 hours of life
  • estimated gestational age of 30 completed weeks or less

You may not qualify if:

  • infant considered non-viable by attending physician
  • infant has cyanotic congenital heart disease
  • infant's parents known to be opposed to blood transfusion
  • either parent has hemoglobinopathies or congenital anemias
  • infant has hemolytic disease
  • infant has severe acute hemorrhage, severe shock, severe sepsis with coagulopathy or requires peri-operative transfusion
  • prior treatment with or intention to treat with erythropoietin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Albany Medical Center

Albany, New York, 12208, United States

Location

Brooklyn Hospital Center

Brooklyn, New York, 11201, United States

Location

Royal Women's Hospital

Melbourne, Victoria, 3053, Australia

Location

Mercy Hospital for Women

Melbourne, Victoria, 3084, Australia

Location

Royal Alexandra Hospital

Edmonton, Alberta, T5H 3T9, Canada

Location

IWK Health Centre

Halifax, Nova Scotia, B3P 1R8, Canada

Location

McMaster University

Hamilton, Ontario, L8S 4J9, Canada

Location

Kingston General Hospital

Kingston, Ontario, K7L 2V7, Canada

Location

Sunnybrook & Women's College Health Science Centre

Toronto, Ontario, M5S 1B2, Canada

Location

Royal Victoria Hospital

Montreal, Quebec, H3A 1A1, Canada

Location

Related Publications (2)

  • Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, Peliowski A, Rios A, LaCorte M, Connelly R, Barrington K, Roberts RS. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr. 2006 Sep;149(3):301-307. doi: 10.1016/j.jpeds.2006.05.011.

  • Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, LaCorte M, Robertson CM, Clarke MC, Vincer MJ, Doyle LW, Roberts RS; PINTOS Study Group. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics. 2009 Jan;123(1):207-13. doi: 10.1542/peds.2008-0338.

MeSH Terms

Conditions

AnemiaBronchopulmonary DysplasiaLeukomalacia, PeriventricularHydrocephalusRetinopathy of Prematurity

Interventions

Erythrocyte Transfusion

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesVentilator-Induced Lung InjuryLung InjuryLung DiseasesRespiratory Tract DiseasesInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEncephalomalaciaVascular DiseasesCardiovascular DiseasesRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Blood Component TransfusionBlood TransfusionBiological TherapyTherapeutics

Study Officials

  • Haresh Kirpalani, MD, MSc

    McMaster University

    PRINCIPAL INVESTIGATOR
  • Robin K Whyte, MD

    Dalhousie University

    PRINCIPAL INVESTIGATOR
  • Robin S Roberts, MTech

    McMaster University

    STUDY DIRECTOR
  • Elizabeth Asztalos, MD, MSc

    Sunnybrook & Women's College Health Sciences Centre

    STUDY DIRECTOR
  • Chad Andersen, MD

    Mercy Hospital for Women

    STUDY DIRECTOR
  • Morris Blajchman, PhD

    McMaster University

    STUDY DIRECTOR
  • Nancy Heddle, MSc

    McMaster University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 16, 2005

Study Start

February 1, 2001

Primary Completion

February 1, 2003

Study Completion

November 1, 2005

Last Updated

September 24, 2015

Record last verified: 2015-09

Locations